News
CDNA
--
0.00%
--
CareDx Showcases Transplantation Innovation and Leadership in Europe at EFI 2021
SOUTH SAN FRANCISCO, Apr 20, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA),...
GlobeNewswire · 23h ago
CareDx to Present at UNOS Transplant Management Forum
Company to showcase its latest integrated solutions for improving care across the whole transplant journeySOUTH SAN FRANCISCO, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the disco...
GlobeNewswire · 4d ago
We're really excited that these genomics companies, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
CNBC.com · 04/12 22:28
Invitae one of our highest conviction names, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
CNBC.com · 04/12 22:16
9 IPOs To Watch For This Week
For the week of July 14, 2014, there are nine IPOs slated to open for trading, including Medical Transcription Billing (NASDAQ: MTBC), previously expected to open last Thursday.
Benzinga · 04/09 19:17
BRIEF-CareDx Announces New HLA Typing Service Offering For Research Purposes
reuters.com · 04/08 11:14
CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings
SOUTH SAN FRANCISCO, Apr 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA),...
GlobeNewswire · 04/05 11:00
CareDx Enhances Leadership Team with Key Appointments
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appoint...
GlobeNewswire · 03/31 11:00
Transplant Diagnostics Market is expected to grow with a CAGR of 7.4% during the forecast period, 2021-2029 | Leading Players – Abbott Laboratories, Biomerieux SA, F Hoffmann La Roche, etc.
Transplant Diagnostics Market 2021 Mar 30, 2021 (Market Insight Reports) -- Straits Research Market report Provides detailed analysis of the Transplant...
Market Insight Reports · 03/30 12:22
CareDx Supports Vir Biotechnology's Clinical Trial Recruitment Efforts For COMET-ICE
CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
Benzinga · 03/23 11:02
Raymond James Maintains a Buy Rating on CareDx (CDNA)
In a report released yesterday, Andrew Cooper from Raymond James maintained a Buy rating on CareDx (CDNA). The company's shares closed last Wednesday at
SmarterAnalyst · 03/18 11:37
CareDx strengthens bioinformatics capabilities with BFS Molecular deal
CareDx (CDNA) announces that it has acquired BFS Molecular S.R.L., a software company focused on NGS-based patient testing solutions.In addition to the acquisition of BFS Molecular, Tim Hague, CEO and Co-Founder
Seekingalpha · 03/17 13:17
BRIEF-Caredx Strengthens Bioinformatics Capabilities With Acquisition Of Bfs Molecular
reuters.com · 03/17 11:47
Press Release: CareDx Strengthens Bioinformatics Capabilities with Acquisition of BFS Molecular
Dow Jones · 03/17 11:00
CareDx Strengthens Bioinformatics Capabilities With Acquisition Of BFS Molecular >CDNA
CareDx Strengthens Bioinformatics Capabilities With Acquisition Of BFS Molecular >CDNA
Dow Jones · 03/17 11:00
CareDx (CDNA), A Top Contributor for Alger Small Cap Focus Fund
Alger, an investment management firm, published its ‘Alger Small Cap Focus Fund’ fourth quarter 2020 investor letter – a copy of which can be downloaded here. In the letter, the fund highlighted their largest portfolio sector weightings, which is in the He...
Insider Monkey · 03/15 16:38
The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 11)
Benzinga · 03/12 12:36
8-K: CareDx, Inc.
(EDGAR Online via COMTEX) -- false 0001217234 0001217234 2021-03-11 2021-03-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/12 05:11
BRIEF-Caredx Names Ankur Dhingra As New Chief Financial Officer
reuters.com · 03/11 22:37
CareDx appoints former Agilent executive as new CFO
CareDx (CDNA) has named Ankur Dhingra as the company’s new Chief Financial Officer effective March 25, 2021.A veteran in finance and accounting with over 25 years of experience, Dhingra was the former
Seekingalpha · 03/11 21:26
Webull provides a variety of real-time CDNA stock news. You can receive the latest news about CareDx through multiple platforms. This information may help you make smarter investment decisions.
About CDNA
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.